Logo image of FLXN

Flexion Therapeutics (FLXN) Stock Analyst Ratings

NASDAQ:FLXN - Nasdaq -

9.12  -0.02 (-0.22%)

After market: 9.121 +0 (+0.01%)

Buy % Consensus

79

ChartMill assigns a Buy % Consensus number of 79% to FLXN. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 12.62. This target is 38.4% above the current price.
FLXN was analyzed by 15 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about FLXN.
In the previous month the buy percentage consensus was at a similar level.
FLXN was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.

Related screens

FLXN Historical Analyst RatingsFLXN Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -43 -39 -35 -31 -27 -23 -19 -15 -11 -7 -3 5 10 15

Price Target & Forecast

Price Low Median Mean High 9.1210.1012.2412.6218.90 - 10.75% 34.21% 38.40% 107.24%

Related screens

FLXN Current Analyst RatingFLXN Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6
Up and Down Grades
Date Firm Action Rating
2021-11-19 Northland Capital Markets Downgrade Outperform -> Market Perform
2021-10-19 HC Wainwright & Co. Downgrade Buy -> Neutral
2021-10-12 BMO Capital Downgrade Outperform -> Market Perform
2021-10-12 Raymond James Downgrade Strong Buy -> Market Perform
2021-10-12 Credit Suisse Downgrade Outperform -> Neutral
2021-08-06 Goldman Sachs Maintains Neutral
2021-08-05 Needham Maintains Buy
2021-05-13 Credit Suisse Maintains Outperform
2021-04-14 Raymond James Maintains Strong Buy
2021-04-14 Credit Suisse Maintains Outperform
2021-03-11 Credit Suisse Maintains Outperform